Drug intelligence / Profile preview

ReNTox

Development stage
Unknown
Lead developer
PharmaResearch Bio
Modality
Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration
Intramuscular
01

Overview

**ReNTox** is a premium botulinum toxin type A neurotoxin manufactured by Pharma Research Bio, a South Korean pharmaceutical company, available in 100-unit or 200-unit lyophilized powder vials for dilution with 0.9% saline prior to injection. It works by blocking acetylcholine release at the neuromuscular junction, temporarily paralyzing targeted muscles to reduce dynamic wrinkles such as glabellar lines, forehead lines, crow's feet, and perioral lines, with effects onset in 3-5 days, peaking at 10-14 days, and lasting 4-8 months. Approved by the Korean Ministry of Food and Drug Safety, it is also used therapeutically for blepharospasm, hemifacial spasm, cervical dystonia, hyperhidrosis, chronic migraine, overactive bladder, and focal spasticity, featuring high purity (99.6%), low diffusion for precision, and hypoallergenic formulation without albumin or gelatin.[1][2][4][7][13]

Brand names
ReNTox
Other names
RentoxRe N ToxReN Tox
02

Targets

SV2A (Synaptic vesicle glycoprotein 2A)VAMP (SNARE Protein Complex)GD3 (Ganglioside GD3)SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on ReNTox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReNTox.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call